How effective is ponatinib?

Ponatinib (Ponatinib, in combination with low-intensity chemotherapy, achieved the primary endpoint of the Phase 3 PhALLCON trial with higher minimal residual disease (MRD)-negative complete response (CR) rates compared with imatinib in adult patients with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). Previous studies have linked MRD negativity to improved long-term patient outcomes.

Ponatinib is the only pan-mutant third-generation tyrosine kinase inhibitor (TKI) targetingBCR, ABL1 (an aberrant tyrosine kinase expressed in chronic myelogenous leukemia (CML) and Ph+ ALL), and also treats all known single, treatment-resistant mutations, such as T315I, the most resistant T315I mutation. Ponatinib is a targeted therapy but is not indicated and is not recommended for the treatment of newly diagnosed CP-CML.

The original drug of Ponatinib has not yet been launched in China, so it is not included in the medical insurance. Domestic patients in need may only purchase it through overseas channels. The Hong Kong original version of Ponatinib specificationsThe price of 45mg*30 tablets per box may be around 40,000 yuan (the price may fluctuate due to the exchange rate), which is expensive. There are also generic ponatinib drugs produced in other countries, which are relatively cheap. The price of 45mg*30 tablets per box produced by Everest Pharmaceutical Factory in Bangladesh may be around 4,000 yuan (the price may fluctuate due to the exchange rate), and its drug ingredients are basically the same as those of the original drug.